Abstracts tagged "Biomarkers"

Abstract Number: 466 • 2017 ACR/ARHP Annual Meeting
Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Martin Pelletier¹, Paul R. Fortin^1,2, Marie-Pier Longchamps¹, Geneviève Parent¹, Hadrien Benk-Fortin¹, Anne-Sophie Julien³, Nathalie Amiable¹, Emmanuelle Rollet-Labelle¹, Laetitia Michou², Louis Bessette² and Philippe A. Tessier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ³Clinical Research Platform, CHU de Québec-Université Laval Research Center, Québec, QC, Canada
Background/Purpose: Methotrexate (MTX) is the first line treatment for patients with rheumatoid arthritis (RA). For over 30% of patients, MTX fails to diminish DAS28 score…
Abstract Number: 771 • 2017 ACR/ARHP Annual Meeting
Serological Biomarkers of Collagen Formation Is Increased in Systemic Sclerosis
Pernille Juhl¹, Mette Mogensen², Line Iversen², Tonny Karlsmark², Morten Karsdal³, Anne-C. Bay-Jensen⁴ and Anne Sofie Siebuhr⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, Herlev, Denmark
Background/Purpose: Systemic sclerosis (SSc) is a multisystem, autoimmune disease characterized by immune dysregulation, vasculopathy and excessive fibrosis of the skin and internal organs. Fibrosis is…
Abstract Number: 1322 • 2017 ACR/ARHP Annual Meeting
Tissue Folate Dysregulation Is Associated with Disease Activity and Methotrexate Response in Collagen-Induced Arthritis
Leon van Haandel¹, Rakesh Singh², Paul Kiptoo³, Teruna Siahaan³, Mara L Becker⁴ and Ryan Funk⁵, ¹2401 Gillham Road, Children's Mercy, Kansas City, MO, ²Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS, ³Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Methotrexate (MTX) is an anti-metabolite inhibitor of folate-dependent biochemical pathways and is effective in reducing disease activity in autoimmune arthritis. This work seeks to…
Abstract Number: 1918 • 2017 ACR/ARHP Annual Meeting
Blood Levels of Complement Split Product iC3b and C3 Outperform Traditional Biochemical Measures of SLE Disease Activity in Associating with Active and Clinically Meaningful Changes
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Martin Schmidt⁵, Robin Bruchas⁶, Nick Staten⁶, Paul Olson⁶, Chad Stiening⁶ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., St. Louis, MO, ⁶Kypha, Inc., Saint Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 2688 • 2017 ACR/ARHP Annual Meeting
Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients
Anne Sofie Siebuhr¹, Satoshi Kubo², Pernille Juhl³, K Nakano⁴, S Nakayamada⁵, Morten Karsdal⁶, Anne-C. Bay-Jensen⁷ and Yoshiya Tanaka⁸, ¹the first department of internal medicine, University of occupational and environmental health, Fukuoka, Japan, ²The first department of internal medicine, University of Occupational en environmental Health, Fukuoka, Japan, ³Nordic Bioscience, Herlev, Denmark, ⁴the first department of internal medicin, University of occupational and environmental health, fukuoka, Japan, ⁵The first department of internal medicine, University of Occupational and environmental Health, fukuoka, Japan, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biomarkers that can monitor the fibrotic burden will aid in trial enrichment and personalized health care in SSc. SSc is associated with internal organ…
Abstract Number: 50 • 2017 ACR/ARHP Annual Meeting
Quality Controls Monitoring As Indicator of Stability in Bone and Cartilage Turnover Markers for Clinical Trials
Yannick Lhoste, Vanessa Di Cataldo, Philippe Vergnaud and Tanja Schubert, Bioclinica Lab, LYON, France
Background/Purpose: Protein biomarkers are widely used in clinical studies to assess drug efficacy, such as bone and cartilage turnover markers in osteoarthritis or rheumatoid arthritis…
Abstract Number: 489 • 2017 ACR/ARHP Annual Meeting
Endotypic Clustering of Rheumatoid Arthritis Patients through the Use of Tissue Specific Serum Biomarkers Identifies Structural Progressors
Joseph Patrick Michele Blair¹, Cecilie Liv Bager¹, Line Mærsk Staunstrup¹, Henning Bay Nielsen¹, Morten Karsdal² and Anne-C. Bay-Jensen³, ¹ProScion, Herlev, Denmark, ²Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Treatment of RA patients is guided by measures of disease activity such as DAS28, best practice recommendation, and less often by a treat-to-target approach.…
Abstract Number: 782 • 2017 ACR/ARHP Annual Meeting
Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen, Marjolein Hoekstra, Johan Bijzet, Wayel H. Abdulahad, Annemieke M.H. Boots and Elisabeth Brouwer, Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: GCA and PMR are closely related inflammatory diseases. The diagnostic criteria of both disorders depend on a combination of clinical features and elevated ESR…
Abstract Number: 1365 • 2017 ACR/ARHP Annual Meeting
Correlation of the Multi-Biomarker Disease Activity Score with Composite Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis
Tate Johnson¹, Kyle A. Register², Cynthia Schmidt³, James R. O'Dell⁴, Ted R. Mikuls⁵, Kaleb Michaud¹ and Bryant R. England⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ³McGoogan Library of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The regular assessment of disease activity is necessary to implement a treat-to-target management approach in RA. The Multi-Biomarker Disease Activity (MBDA) Score is a…
Abstract Number: 1921 • 2017 ACR/ARHP Annual Meeting
Urine Angiostatin and VCAM-1 Surpass Conventional Metrics in Predicting Elevated Renal Pathology Activity Indices in Lupus Nephritis
Samar Soliman^1,2, Fatma Mohamed³, Faten Ismail³, Ramesh Saxena⁴ and Chandra Mohan², ¹Rheumatology and rehabilitation, University of Minya, Minya, Egypt, ²Biomedical Engineering, University of Houston, Houston, TX, ³Rheumatology and Rehabilitation, University of Minya, Minya, Egypt, ⁴Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The goal of this study is to investigate how urinary angiostatin, VCAM-1 and established measures of renal function relate to specific histologic findings in…
Abstract Number: 2815 • 2017 ACR/ARHP Annual Meeting
Pathological Roles By Siglec and Type I Interferons for the Development of Autoimmune Congenital Heart Block
Robert M. Clancy¹, Marc Halushka² and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Given that diseases associated with anti-SSA/Ro such as SLE and Sjögren’s syndrome associate with an upregulation of type I interferons, recent attention has focused…
Abstract Number: 66 • 2017 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Profiling of OA PBMCs Reveals Slowed Epigenetic Aging Among Rapid Radiographic Progressors: Data from the Osteoarthritis Initiative (OAI)
Alexander Rivas¹, Madison Andrews² and Matlock A. Jeffries³, ¹Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Department of Medicine, Division of Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Extensive evidence has correlated epigenetic alterations in articular tissues with both the presence and progression of human osteoarthritis. A recent study demonstrated that accelerated…
Abstract Number: 649 • 2017 ACR/ARHP Annual Meeting
Role of Eicosanoids As Biomarkers in Psoriatic Arthritis
Roxana Coras^1,2, Arthur Kavanaugh¹, Doquyen H. Huynh¹, Aladdin Shadyab³, Sara Marsal⁴, Oswald Quehenberger⁵ and Monica Guma¹, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Barcelona, Spain, ³Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴Rheumatology Research Unit, Vall d'Hebron Hospital, Barcelona, Spain, ⁵Pharmacology, Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease affecting the joints and connective tissue and is associated with psoriasis of the skin and nails. There…
Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 1389 • 2017 ACR/ARHP Annual Meeting
Serum Progranulin Antibodies (PGRN-abs) in Rheumatoid Arthritis Patients Being Negative for RF-IgM and ACCP-IgG
Gunter Assmann¹, Silke Zinke², Moritz Gerling³, Natalie Fadle³, Klaus Dieter Preuss³, Michael Pfreundschuh³ and Lorenz Thurner³, ¹Medicine I, University Medical School of Saarland, 66424, Germany, ²Rheumapraxis, Rheumatology Center Berlin - Lichtenberg, Berlin, Germany, ³Medicine I, Jose Carreras Center, University of Saarland, Homburg, Germany
Background/Purpose: Until recently, most research on progranulin (PGRN) had been focused on its role in neurogenerative diseases as frontotemporal dementia. After the detection of elevated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].